🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06731946
Active, not recruiting Observational

Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms

NCT06731946 · tracked via the Priya Life Science China tracker
Sponsor
Yibin Fang
Phase
Observational
Started
2024-11-29
Last updated
2024-12-13

Condition(s) studied

Intracranial Arterial Aneurysm

Investigational drug(s) / intervention(s)

Flow diverting

Flow diverting: Flow diverter has become the standardized treatment method for Intracranial aneurysms (IAs), which is different from angioplasty, coiling, etc.

Study summary

Safety and Efficacy of the Surpass Evolve Flow Diverter in Treating Intracranial Aneurysms

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 years with a confirmed diagnosis of intracranial aneurysm. 2. Imaging studies confirming suitability for Surpass Evolve Flow Diverter treatment. 3. Aneurysms meeting flow diverter treatment indications (e.g., aneurysms larger than 4 mm). 4. At least six months of follow-up data available post-treatment. Exclusion Criteria: 1. Patients with acutely ruptured aneurysms or significant bleeding. 2. Patients with incomplete data or insufficient follow-up records.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shanghai Fourth People's Hospital Shanghai China
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06731946 on ClinicalTrials.gov ↗ ← All trials in China